BTK and B-cell chronic lymphocytic leukemia: Zanubrutinib (BGB-3111) is a second-generation BTK inhibitor that has a promising ORR (96.2%) with low toxicity in CLL/SLL patients in a phase 1 trial (NCT02343120).207 Phase 2 trials of zanubrutinib in relapsed or refractory DLBCL (NCT03145064), MZL (NCT03846427), and MCL (NCT03206970), as well as phase 3 trials (NCT03734016 and NCT03053440) comparing zanubrutinib with ibrutinib in patients with relapsed or refractory CLL or WM, are ongoing.